Results 141 to 150 of about 12,025 (204)

Long-acting muscarinic antagonist and long-acting β₂-agonist combination for the treatment of maintenance therapy-naïve patients with chronic obstructive pulmonary disease: a narrative review. [PDF]

Ther Adv Respir Dis
Buhl R, Miravitlles M, Anzueto A, Brunton S.   +3 more
europepmc   +1 more source

Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate. [PDF]

Chronic Obstr Pulm Dis, 2019
Mahler DA, Ohar JA, Barnes CN, Moran EJ, Pendyala S, Crater GD.   +5 more
europepmc   +1 more source

Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β₂-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis. [PDF]

Adv Ther, 2020
Ferguson GT, Darken P, Ballal S, Siddiqui MK, Singh B, Attri S, Holmgren U, de Nigris E.   +7 more
europepmc   +1 more source

Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease. [PDF]

Ann Pharmacother, 2019
Pleasants RA.
europepmc   +1 more source

Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study. [PDF]

Pulm Ther, 2019
Hahn B, Stanford RH, Goolsby Hunter A, Essoi B, White J, Ray R.   +5 more
europepmc   +1 more source

Long-acting muscarinic antagonist and long-acting β2-agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery. [PDF]

Mol Clin Oncol, 2018
Makino T, Otsuka H, Hata Y, Koezuka S, Azuma Y, Isobe K, Sugino K, Ebihara S, Homma S, Iyoda A.   +9 more
europepmc   +1 more source

A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β₂-Agonist (LABA) Combinations in COPD. [PDF]

Pulm Ther, 2017
Sion KYJ, Huisman EL, Punekar YS, Naya I, Ismaila AS.   +4 more
europepmc   +1 more source

Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis. [PDF]

Int J Chron Obstruct Pulmon Dis, 2018
Hurst JR, Dilleen M, Morris K, Hills S, Emir B, Jones R.   +5 more
europepmc   +1 more source

Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β₂-agonist fixed-dose combinations in COPD. [PDF]

Ther Adv Respir Dis, 2019
Siddiqui MK, Shukla P, Jenkins M, Ouwens M, Guranlioglu D, Darken P, Biswas M.   +6 more
europepmc   +1 more source

A new therapeutic choice for COPD: glycopyrronium bromide, a long-acting muscarinic antagonist

Folia Pharmacologica Japonica, 2013
Yoshisue, Hajime, Kozawa, Masanari, Hiratsuka, Maki, Nakanishi, Masaki   +3 more
openaire   +3 more sources